MARKET

THMO

THMO

ThermoGenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.430
-0.180
-6.90%
After Hours: 2.440 +0.01 +0.42% 17:26 10/22 EDT
OPEN
2.600
PREV CLOSE
2.610
HIGH
2.622
LOW
2.360
VOLUME
859.69K
TURNOVER
--
52 WEEK HIGH
14.18
52 WEEK LOW
1.630
MARKET CAP
16.30M
P/E (TTM)
-0.5787
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ThermoGenesis up 7% on U.S. emergency use extension for COVID-19 antibody test
Nano cap ThermoGenesis ([[THMO]] +7.2%) perks up on a 10x surge in volume in apparent response to the FDA nod extending emergency use authorization for its SARS-CoV-2 IgM/IgG blood test
Seekingalpha · 2d ago
Facilitating the 'Vaccine Era' of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) today announced that it has received notification from the United States Patent and Trademark Office (USPTO) of its intent to issue U.S. Patent No. 10,823,746 on November 3, for the Company's new breakthrough lateral flow immunoassay test reader technology, the ThermoGenesis Reader. The application leading to this patent, titled, "Lateral Flow Immunoassay Test Reader and Method of Use," was accepted by USPTO under its recently announced COVID-19 Prioritized Examination Program.
PR Newswire · 2d ago
Precigen and Medigus lead Healthcare gainers; Mallinckrodt and GeoVax Labs lead losers
Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGenesis (THMO) -8%.
Seekingalpha · 10/09 15:01
ThermoGenesis Holdings, Inc. (NASDAQ:THMO): Are Analysts Optimistic?
We feel now is a pretty good time to analyse ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) business as it appears the...
Simply Wall St. · 09/11 20:34
ThermoGenesis to outline product strategy in COVID-19 at LD Micro 500 conference
ThermoGenesis Holdings (THMO) along with its joint venture, ImmuneCyte plans to roll out a comprehensive diagnostic and therapeutic product line to fight COVID-19 pandemic.The multi-pronged strategy will combine diagnostic, therapeutic
Seekingalpha · 09/02 13:07
ThermoGenesis To Roll Out A 'Comprehensive Diagnostic And Therapeutic Product Line' For COVID-19
RANCHO CORDOVA, Calif., Sept 2, 2020 /PRNewswire/ --ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its
Benzinga · 09/02 12:38
ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global
PR Newswire · 09/02 12:30
ThermoGenesis Holdings to Participate in Investor Conferences in September
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management's participation in the following investor conferences in September.
PR Newswire · 08/31 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of THMO. Analyze the recent business situations of ThermoGenesis Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average THMO stock price target is 9.50 with a high estimate of 9.50 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 283.97K
% Owned: 4.23%
Shares Outstanding: 6.71M
TypeInstitutionsShares
Increased
6
175.70K
New
11
-89.15K
Decreased
2
2.35K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Office Equipment
+1.16%
Technology Equipment
-0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Xiaochun Xu
Chief Financial Officer/Secretary
Jeffery Cauble
Independent Director
Debra Donaghy
Independent Director
Russell Medford
Independent Director
Joseph Thomis
Independent Director
Mark Westgate
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About THMO
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Thermogenesis Holdings Inc stock information, including NASDAQ:THMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THMO stock methods without spending real money on the virtual paper trading platform.